Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Blood Advances|January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AMLOnyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
Leukemia & Lymphoma|August 27, 2021
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosisRami Komrokji, Megan Melody, Najla Al Ali, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Cardio-Oncology (London, England)|May 9, 2026
Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosisAlexis Behne Sharma, Elicia Wang, Sruthi Selvakumar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2019
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with MyelofibrosisRoni Tamari, Franck Rapaport, Nan Zhang, et al.
Hemasphere|February 13, 2025
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDSAngela Consagra, Luca Lanino, Najla H Al Ali, et al.
Leukemia|August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patientsBarbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with MyelofibrosisJohn Mascarenhas, Anna Rita Migliaccio, Heidi Kosiorek, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Pageof 4